These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37000339)

  • 1. Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use.
    Heo YA
    CNS Drugs; 2023 May; 37(5):467-473. PubMed ID: 37000339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efgartigimod: First Approval.
    Heo YA
    Drugs; 2022 Feb; 82(3):341-348. PubMed ID: 35179720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
    Saccà F; Barnett C; Vu T; Peric S; Phillips GA; Zhao S; Qi CZ; Gelinas D; Chiroli S; Verschuuren JJGM
    J Neurol; 2023 Apr; 270(4):2096-2105. PubMed ID: 36598575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
    Habib AA; Sacconi S; Antonini G; Cortés-Vicente E; Grosskreutz J; Mahuwala ZK; Mantegazza R; Pascuzzi RM; Utsugisawa K; Vissing J; Vu T; Wiendl H; Boehnlein M; Greve B; Woltering F; Bril V
    Ther Adv Neurol Disord; 2024; 17():17562864241273036. PubMed ID: 39297052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
    Howard JF; Bril V; Vu T; Karam C; Peric S; De Bleecker JL; Murai H; Meisel A; Beydoun SR; Pasnoor M; Guglietta A; Van Hoorick B; Steeland S; T'joen C; Utsugisawa K; Verschuuren J; Mantegazza R;
    Front Neurol; 2023; 14():1284444. PubMed ID: 38318236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience.
    Dos Santos JBR; Gomes RM; da Silva MRR
    Expert Rev Clin Immunol; 2022 Sep; 18(9):879-888. PubMed ID: 35892247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
    Lien PW; Joshi M; Tice JA; Agboola F; Nikitin D; Withanawasam V; Jatoi S; Touchette DR
    J Manag Care Spec Pharm; 2024 Jun; 30(6):517-527. PubMed ID: 38824625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
    Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
    Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
    Howard JF; Vu T; Li G; Korobko D; Smilowski M; Liu L; Gistelinck F; Steeland S; Noukens J; Van Hoorick B; Podhorna J; Borgions F; Li Y; Utsugisawa K; Wiendl H; De Bleecker JL; Mantegazza R;
    Neurotherapeutics; 2024 Sep; 21(5):e00378. PubMed ID: 39227284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.
    Luo S; Jiang Q; Zeng W; Wang Q; Zou Z; Yu Y; Hong D; Zeng Q; Tan S; Zhang Z; Zhang Y; Guo X; Chen J; Zhao Z; Huang S; Shi J; Chen Y; Du L; Yan C; Xi J; Song J; Zhao C;
    Ann Clin Transl Neurol; 2024 Aug; 11(8):2212-2221. PubMed ID: 38973109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    Pane C; Di Stefano V; Cuomo N; Sarnataro A; Vinciguerra C; Bevilacqua L; Brighina F; Rini N; Puorro G; Marsili A; Garibaldi M; Fionda L; Saccà F
    J Neurol; 2024 Sep; 271(9):6209-6219. PubMed ID: 39080054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Katyal N; Halldorsdottir K; Govindarajan R; Shieh P; Muley S; Reyes P; Leung KK; Mullen J; Milani-Nejad S; Korb M; Goyal NA; Mozaffar T; Goyal N; Habib AA; Muppidi S
    Muscle Nerve; 2023 Nov; 68(5):762-766. PubMed ID: 37695277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming therapeutic challenges: Successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod.
    Sorrenti B; Laurini C; Bosco L; Strano CMM; Scarlato M; Gastaldi M; Filippi M; Previtali SC; Falzone YM
    Eur J Neurol; 2024 Jul; 31(7):e16306. PubMed ID: 38716750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
    Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
    Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.
    Singer M; Khella S; Bird S; McIntosh P; Paudyal B; Wadhwani A; Quinn C; Karam C
    Muscle Nerve; 2024 Jan; 69(1):87-92. PubMed ID: 37990374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update of the pharmacological treatment options for generalized myasthenia gravis in adults with anti-acetylcholine receptor antibodies.
    Riley TR; Douglas JS; Wang C; Bowser KM
    Am J Health Syst Pharm; 2023 May; 80(11):652-662. PubMed ID: 36775959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.